Knight Therapeutics (GUD) Competitors

C$8.36 +0.01 (+0.12%)

As of 05/25/2026 04:00 PM Eastern

GUD vs. BHC, CRON, THCX, TLRY, and DHT.UN

Should you buy Knight Therapeutics stock or one of its competitors? MarketBeat compares Knight Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Knight Therapeutics include Bausch Health Companies (BHC), Cronos Group (CRON), Hydropothecary (THCX), Tilray Brands (TLRY), and DRI Healthcare Trust (DHT.UN). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Knight Therapeutics compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

In the previous week, Bausch Health Companies had 12 more articles in the media than Knight Therapeutics. MarketBeat recorded 12 mentions for Bausch Health Companies and 0 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.00 beat Bausch Health Companies' score of -0.25 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch Health Companies	Neutral
Knight Therapeutics	Neutral

Knight Therapeutics has a net margin of 1.10% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-13.54%	120.43%	4.16%
Knight Therapeutics	1.10%	0.73%	0.51%

Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	C$10.53B	0.27	-C$125.65M	-C$3.24	N/A
Knight Therapeutics	C$510.45M	1.61	-C$30.73M	C$0.06	139.33

10.0% of Bausch Health Companies shares are held by institutional investors. Comparatively, 23.2% of Knight Therapeutics shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Knight Therapeutics has a consensus target price of C$9.50, suggesting a potential upside of 13.64%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bausch Health Companies has a beta of 0.631102, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.214451, suggesting that its stock price is 121% less volatile than the broader market.

Summary

Knight Therapeutics beats Bausch Health Companies on 11 of the 16 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Knight Therapeutics (TSE:GUD) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

23.2% of Knight Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of Cronos Group shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by company insiders. Comparatively, 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Knight Therapeutics has a beta of -0.214451, indicating that its share price is 121% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.11805, indicating that its share price is 12% more volatile than the broader market.

Knight Therapeutics has a net margin of 1.10% compared to Cronos Group's net margin of -1.29%. Knight Therapeutics' return on equity of 0.73% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	1.10%	0.73%	0.51%
Cronos Group	-1.29%	-0.19%	-3.73%

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Cronos Group	Neutral

Knight Therapeutics presently has a consensus price target of C$9.50, indicating a potential upside of 13.64%. Cronos Group has a consensus price target of C$4.75, indicating a potential upside of 24.67%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Knight Therapeutics has higher revenue and earnings than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$510.45M	1.61	-C$30.73M	C$0.06	139.33
Cronos Group	C$159.54M	8.92	-C$32.78M	N/A	N/A

Summary

Knight Therapeutics beats Cronos Group on 7 of the 12 factors compared between the two stocks.

How does Knight Therapeutics compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Knight Therapeutics has a consensus price target of C$9.50, suggesting a potential upside of 13.64%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Hydropothecary's average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company	Overall Sentiment
Hydropothecary	Neutral
Knight Therapeutics	Neutral

Hydropothecary has higher earnings, but lower revenue than Knight Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hydropothecary	N/A	N/A	N/A	N/A	N/A
Knight Therapeutics	C$510.45M	1.61	-C$30.73M	C$0.06	139.33

23.2% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Knight Therapeutics has a net margin of 1.10% compared to Hydropothecary's net margin of 0.00%. Knight Therapeutics' return on equity of 0.73% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hydropothecary	N/A	N/A	N/A
Knight Therapeutics	1.10%	0.73%	0.51%

Summary

Knight Therapeutics beats Hydropothecary on 9 of the 9 factors compared between the two stocks.

How does Knight Therapeutics compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Tilray Brands currently has a consensus target price of C$13.30, indicating a potential upside of 77.33%. Knight Therapeutics has a consensus target price of C$9.50, indicating a potential upside of 13.64%. Given Tilray Brands' higher probable upside, equities analysts clearly believe Tilray Brands is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Tilray Brands has a beta of 3.243166, indicating that its share price is 224% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.214451, indicating that its share price is 121% less volatile than the broader market.

Knight Therapeutics has a net margin of 1.10% compared to Tilray Brands' net margin of -158.75%. Knight Therapeutics' return on equity of 0.73% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-158.75%	-88.06%	-1.41%
Knight Therapeutics	1.10%	0.73%	0.51%

Knight Therapeutics has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$858.28M	1.05	-C$183.24M	-C$14.63	N/A
Knight Therapeutics	C$510.45M	1.61	-C$30.73M	C$0.06	139.33

In the previous week, Tilray Brands' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company	Overall Sentiment
Tilray Brands	Neutral
Knight Therapeutics	Neutral

4.1% of Tilray Brands shares are held by institutional investors. Comparatively, 23.2% of Knight Therapeutics shares are held by institutional investors. 0.7% of Tilray Brands shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Knight Therapeutics beats Tilray Brands on 11 of the 14 factors compared between the two stocks.

How does Knight Therapeutics compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

DRI Healthcare Trust has a net margin of 5.02% compared to Knight Therapeutics' net margin of 1.10%. DRI Healthcare Trust's return on equity of 2.06% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Knight Therapeutics	1.10%	0.73%	0.51%

0.6% of DRI Healthcare Trust shares are owned by institutional investors. Comparatively, 23.2% of Knight Therapeutics shares are owned by institutional investors. 0.1% of DRI Healthcare Trust shares are owned by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, DRI Healthcare Trust had 3 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for DRI Healthcare Trust and 0 mentions for Knight Therapeutics. DRI Healthcare Trust's average media sentiment score of 1.00 beat Knight Therapeutics' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company	Overall Sentiment
DRI Healthcare Trust	Positive
Knight Therapeutics	Neutral

DRI Healthcare Trust has a beta of 0.347429, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.214451, suggesting that its share price is 121% less volatile than the broader market.

DRI Healthcare Trust has higher earnings, but lower revenue than Knight Therapeutics. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$163.77M	5.69	C$9.73M	-C$0.90	N/A
Knight Therapeutics	C$510.45M	1.61	-C$30.73M	C$0.06	139.33

DRI Healthcare Trust presently has a consensus target price of C$25.50, indicating a potential upside of 50.44%. Knight Therapeutics has a consensus target price of C$9.50, indicating a potential upside of 13.64%. Given DRI Healthcare Trust's higher possible upside, equities research analysts plainly believe DRI Healthcare Trust is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

DRI Healthcare Trust beats Knight Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Knight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUD vs. The Competition

Export

Metric	Knight Therapeutics	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$820.78M	C$2.22B	C$6.46B	C$12.16B
Dividend Yield	N/A	2.95%	2.76%	6.20%
P/E Ratio	139.33	5.16	21.22	37.64
Price / Sales	1.61	1,770.59	553.92	11.68
Price / Cash	3.85	10.18	43.49	82.29
Price / Book	1.05	10.61	10.37	4.50
Net Income	-C$30.73M	C$20.70B	C$3.57B	C$299.09M
7 Day Performance	1.09%	8.23%	6.40%	2.48%
1 Month Performance	10.88%	3.77%	3.52%	1.47%
1 Year Performance	43.64%	22.84%	34.02%	53.55%

Knight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUD Knight Therapeutics	1.0988 of 5 stars	C$8.36 +0.1%	C$9.50 +13.6%	+44.4%	C$820.78M	C$510.45M	139.33	725
BHC Bausch Health Companies	0.7298 of 5 stars	C$7.56 flat	N/A	+26.1%	C$2.82B	C$10.53B	N/A	19,900
CRON Cronos Group	2.4406 of 5 stars	C$3.69 flat	C$4.75 +28.7%	+36.6%	C$1.38B	C$159.54M	N/A	450
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume
TLRY Tilray Brands	1.2797 of 5 stars	C$7.42 flat	C$13.30 +79.2%	+25.0%	C$887.46M	C$858.28M	N/A	2,650

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:GUD) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Knight Therapeutics (GUD) Competitors

GUD vs. BHC, CRON, THCX, TLRY, and DHT.UN

How does Knight Therapeutics compare to Bausch Health Companies?

Summary

How does Knight Therapeutics compare to Cronos Group?

Summary

How does Knight Therapeutics compare to Hydropothecary?

Summary

How does Knight Therapeutics compare to Tilray Brands?

Summary

How does Knight Therapeutics compare to DRI Healthcare Trust?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUD vs. The Competition

Knight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Knight Therapeutics (GUD) Competitors

GUD vs. BHC, CRON, THCX, TLRY, and DHT.UN

How does Knight Therapeutics compare to Bausch Health Companies?

Does the media prefer BHC or GUD?

Is BHC or GUD more profitable?

Which has stronger earnings & valuation, BHC or GUD?

Do institutionals and insiders hold more shares of BHC or GUD?

Do analysts recommend BHC or GUD?

Which has more volatility and risk, BHC or GUD?

Summary

How does Knight Therapeutics compare to Cronos Group?

Do institutionals & insiders believe in GUD or CRON?

Which has more volatility & risk, GUD or CRON?

Is GUD or CRON more profitable?

Does the media refer more to GUD or CRON?

Do analysts recommend GUD or CRON?

Which has preferable valuation & earnings, GUD or CRON?

Summary

How does Knight Therapeutics compare to Hydropothecary?

Do analysts recommend THCX or GUD?

Does the media favor THCX or GUD?

Which has preferable earnings & valuation, THCX or GUD?

Do institutionals & insiders hold more shares of THCX or GUD?

Is THCX or GUD more profitable?

Summary

How does Knight Therapeutics compare to Tilray Brands?

Do analysts prefer TLRY or GUD?

Which has more volatility & risk, TLRY or GUD?

Is TLRY or GUD more profitable?

Which has higher valuation & earnings, TLRY or GUD?

Does the media prefer TLRY or GUD?

Do institutionals & insiders believe in TLRY or GUD?

Summary

How does Knight Therapeutics compare to DRI Healthcare Trust?

Is DHT.UN or GUD more profitable?

Do institutionals & insiders believe in DHT.UN or GUD?

Does the media refer more to DHT.UN or GUD?

Which has more risk and volatility, DHT.UN or GUD?

Which has stronger valuation & earnings, DHT.UN or GUD?

Do analysts recommend DHT.UN or GUD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUD vs. The Competition

Knight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools